The Leiden Bio Science Park company Eyesiu Medicines BV received “Notice of Allowance” for its patent application ““Pegylated lipid nanoparticle with bioactive lipophilic compound” (
US20180235896A1; US15/751,170; US 10,525,012 B2) from the US Patent and Trademark Office (USPTO). The application is pending in the EU, Russia, China, South Korea, Japan, Taiwan and India. The allowable claims for the nanoparticles comprise one or more phospholipids and at least one of an acylethanolamide (such as the endocannabinoids 2-arachidonoylglycerol (2-AG), arachidonoylethanolamide (AEA or anandamide), oleoylethanolamide (OAE), or palmitoylethanolamide (PEA)) and a macrolide (such as tacrolimus, sirolimus or cyclosporine A), wherein the nanoparticle has a surface comprising a water soluble polymer (such as PEG).
“Being rewarded with an issued US patent for the core of our invention is very gratifying and a validation of Eyesiu’s series of related therapeutics and nutraceutical products in development and available on the market”, comments Dr. Pieter J. Gaillard, founder and CEO of Eyesiu. “This first allowance of Eyesiu’s patent application by the USPTO with broad and commercially relevant claims supports our belief that the technology will also obtain similar product protection in the other geographies where the application is currently pending”, Gaillard adds.
Eyesiu’s therapeutics and nutraceuticals
Eyesiu has developed therapeutics, in pre-clinical stage, targeting a wide range of indications in neurology, ophthalmology, dermatology and pulmonology. The company has also developed nutraceuticals (food supplements) that support its users to maintain pain-free and healthier brain, eyes, lungs, skin and/or hair: the first one is a spray bottle with PEA, comprising a lipid-based sublingual, skin and mouth spray formulation for convenient, effective, fast and sustained delivery, and is for sale through Eyesiu’s health care division (Eyesiu Care) via www.PEArlboost.com
About Eyesiu Medicines BV and Eyesiu Care
For more information see www.eyesiu-medicines.com and www.eyesiu-care.com
For further information, please contact
Eyesiu Medicines BV | Pieter J. Gaillard | info@eyesiu.com